Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$16.98 USD
+0.33 (1.98%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $17.00 +0.02 (0.12%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Company Summary
Cranbury, NJ-based Rocket Pharmaceuticals is a clinical-stage biotech company focused on developing novel gene therapies targeting multiple therapeutic areas, including cardiovascular (CV) and hematology.
In hematology, the company’s three gene therapy candidates are in clinical development, namely Kresladi (RP-L201 or marnetegragene autotemcel), RP-L102 and RP-L301. All of these therapies utilize lentiviral vectors (LV) (gene delivery vehicle) for genetic modifications.
A biologics license application (BLA) seeking approval of Kresladi for treating severe leukocyte adhesion deficiency-I (LAD-I) is under review with the FDA,. In June 2024, the ...
Company Summary
Cranbury, NJ-based Rocket Pharmaceuticals is a clinical-stage biotech company focused on developing novel gene therapies targeting multiple therapeutic areas, including cardiovascular (CV) and hematology.
In hematology, the company’s three gene therapy candidates are in clinical development, namely Kresladi (RP-L201 or marnetegragene autotemcel), RP-L102 and RP-L301. All of these therapies utilize lentiviral vectors (LV) (gene delivery vehicle) for genetic modifications.
A biologics license application (BLA) seeking approval of Kresladi for treating severe leukocyte adhesion deficiency-I (LAD-I) is under review with the FDA,. In June 2024, the FDA issued a complete response letter (CRL) to the BLA for Kresladi. Meanwhile, RP-L102 is being developed for the treatment of fanconi anemia (FA) and RP-L301 is being sy=tuided for treating pyruvate kinase deficiency (PKD). Both the candidates are in mid-stage development.
Rocket Pharmaceuticals is developing adeno-associated virus (AAV) gene therapies to target genetic CV indications caused by mutations or defects in different genes. The most advanced AAV-based candidate in the company’s pipeline is RP-A501, which is in a mid-stage study for treating Danon disease (DD).
Another AAV-based gene therapy candidate is RP-A601, which is in early-stage development for arrhythmogenic cardiomyopathy (ACM). It also plans to start clinical studies on a new gene therapy candidate for the treatment of dilated cardiomyopathy (DCM).
Rocket Pharmaceuticals’ portfolio is currently devoid of any approved product. As a result, the company has yet to generate any revenues.
General Information
Rocket Pharmaceuticals, Inc
9 CEDARBROOK DRIVE
CRANBURY, NJ 08512
Phone: 609-659-8001
Fax: 646-224-9585
Web: http://www.rocketpharma.com
Email: investors@rocketpharma.com
| Industry | Medical - Biomedical and Genetics |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 9/30/2024 |
| Exp Earnings Date | 11/4/2024 |
EPS Information
| Current Quarter EPS Consensus Estimate | -0.78 |
| Current Year EPS Consensus Estimate | -2.98 |
| Estimated Long-Term EPS Growth Rate | NA |
| Exp Earnings Date | 11/4/2024 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 16.65 |
| 52 Week High | 32.53 |
| 52 Week Low | 15.98 |
| Beta | 1.09 |
| 20 Day Moving Average | 641,845.94 |
| Target Price Consensus | 47.85 |
| 4 Week | 3.47 |
| 12 Week | -10.82 |
| YTD | -43.34 |
| 4 Week | 3.88 |
| 12 Week | -16.81 |
| YTD | -52.83 |
| Shares Outstanding (millions) | 91.01 |
| Market Capitalization (millions) | 1,545.43 |
| Short Ratio | NA |
| Last Split Date | 1/5/2018 |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | NA |
| Change in Payout Ratio | NA |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | NA |
| Trailing 12 Months | NA |
| PEG Ratio | NA |
| vs. Previous Year (Q0/Q-4) | 9.76% |
| vs. Previous Quarter (Q0/Q-1) | -12.12% |
| vs. Previous Year (Q0/Q-4) | NA% |
| vs. Previous Quarter (Q0/Q-1) | NA% |
| Price/Book | 4.01 |
| Price/Cash Flow | NA |
| Price / Sales | NA |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | -54.47 |
| 3/31/24 | -53.10 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | -47.99 |
| 3/31/24 | -46.90 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 7.79 |
| 3/31/24 | 10.47 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 7.79 |
| 3/31/24 | 10.47 |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 4.24 |
| 3/31/24 | 4.87 |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 0.05 |
| 3/31/24 | 0.04 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 4.80 |
| 3/31/24 | 4.20 |